Clinical data | |
---|---|
Pronunciation | /ˌraɪbəˈvaɪrɪn/ RY-bə-VY-rin |
Trade names | Copegus, Rebetol, Virazole, other[1] |
Other names | 1-(β-D-Ribofuranosyl)-1"H"-1,2,4-triazole-3-carboxamide, tribavirin (BAN UK) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605018 |
License data | |
Pregnancy category |
|
Routes of administration | Oral, Inhalation |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 64%[5] |
Protein binding | 0%[5] |
Metabolism | liver and intracellularly[5] |
Elimination half-life | 298 hours (multiple dose); 43.6 hours (single dose)[5] |
Excretion | Urine (61%), faeces (12%)[5] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
NIAID ChemDB | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.164.587 |
Chemical and physical data | |
Formula | C8H12N4O5 |
Molar mass | 244.207 g·mol−1 |
3D model (JSmol) | |
Melting point | 166 to 168 °C (331 to 334 °F) |
| |
| |
(verify) |
Ribavirin, also known as tribavirin, is an antiviral medication used to treat RSV infection, hepatitis C and some viral hemorrhagic fevers.[1] For hepatitis C, it is used in combination with other medications such as simeprevir, sofosbuvir, peginterferon alfa-2b or peginterferon alfa-2a.[1] It can also be used for viral hemorrhagic fevers, specifically for Lassa fever, Crimean–Congo hemorrhagic fever, and Hantavirus infection with exceptions for Ebola or Marburg infections.[1] Ribavirin is usually taken orally (swallowed by mouth) or inhaled.[1] Despite widespread usage, it has faced scrutiny in 2010 because of lack of efficacy in treating viral infections as it has historically been prescribed for.[6][7]
Its common side effects include fatigue, headache, nausea, fever, muscle pains, and an irritable mood.[1] Serious side effects include red blood cell breakdown, liver problems, and allergic reactions.[1] Its use during pregnancy can bring harm to the baby.[1] Effective birth control is recommended for both males and females for at least seven months during and after use.[8] The mechanism of action of ribavirin is not entirely clear.[1]
Ribavirin was patented in 1971 and approved for medical use in 1986.[9] It is on the World Health Organization's List of Essential Medicines.[10] It is available as a generic medication.[1]
Safrin_2024
was invoked but never defined (see the help page).Drugs.com_2023
was invoked but never defined (see the help page).